Rinsho Shinkeigaku (Clinical Neurology)

Symposium 12

Pathomechanism and prevalence of sporadic inclusion body myositis (sIBM)

Naoki Suzuki, M.D.1), Maki Tateyama, M.D.1), Hitoshi Warita, M.D.1), Rumiko Izumi, M.D.1), Ichizo Nishino, M.D.2) and Masashi Aoki, M.D.1)

1)Department of Neurology, Tohoku University School of Medicine
2)Department of Neuromuscular Research, National Institute of Neuroscience,
National Center of Neurology and Psychiatry (NCNP)

Sporadic inclusion body myositis (sIBM) is an intractable and progressive skeletal muscle disease of unknown cause and without effective treatment. The etiology of sIBM is still unknown, however genetic factors, aging, life styles, environmental factors may be involved. sIBM is generally refractory to current therapy, such as steroid or immunosuppressants. To elucidate the pathomechanism of sIBM is the most important way to make therapeutic approach. In this review we estimated the prevalence of sIBM in Japan and discuss the pathomechanism of sIBM.
Full Text of this Article in Japanese PDF (242K)

(CLINICA NEUROL, 51: 964|966, 2011)
key words: sporadic inclusion body myositis (sIBM), prevalence, muscle pathology, rimmed vacuole, inflammation

(Received: 19-May-11)